Table 1.

Most frequent (≥4 or more patients in part A and/or >3 pts in part B) treatment-related adverse events

	Part A				Part B
	Efti (1 mg)/ pembro (n=6)	Efti (6 mg)/ pembro (n=6)	Efti (30 mg)/ pembro (n=6)	Total (n=18)	Efti (30 mg)/ pembro (n=6)
Fatigue	4 (66.7)	1 (16.7)	3 (50.0)	8 (44.4)	5 (83.3)
Injection site erythema	–	–	1 (16.7)	1 (5.6)	4 (66.7)
Edema peripheral	–	–	–	–	4 (66.7)
Diarrhea	2 (33.3)	–	3 (50.0)	5 (27.8)	1 (16.7)
Nausea	1 (16.7)	2 (33.3)	2 (33.3)	5 (27.8)	2 (33.3)
Rash	1 (16.7)	2 (33.3)	2 (33.3)	5 (27.8)	4 (66.7)
Arthralgia	2 (33.3)	1 (16.7)	1 (16.7)	4 (22.2)	4 (66.7)

Results shown as: number of patients with adverse event (%).